here’s more than one way to attack PCSK9 and lower cholesterol, but investors seem to be losing hope that the field’s next generation of drugs will ever make a splash on the market.

The Medicines Company, which is years away from selling its PCSK9 drug, saw its share price tumble by about 15 percent on Friday despite presenting positive data, as Wall Street reacted to disappointing clinical results from Amgen’s approved Repatha that have changed the landscape in biotech.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories